Co-Diagnostics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.70
Dividend & YieldN/A$ (N/A)
Beta -0.61
Market capitalization 92.44M
Operating cash flow 15.46M
ESG Scores unknown

Company description

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Sector: Healthcare - Industry: Medical Devices

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -108.39k -225.34k 4.06M -455.24k
Total Cashflows From Investing Activities -380.34k -435.25k -5.82M 4.1M
Net Borrowings 2M
Total Cash From Financing Activities 1.88M 5.9M 19.74M 450.4k
Change To Operating Activities 900.67k -292.46k -6.46k -2.05M
Issuance Of Stock 30k 5.5M 21.2M 450.4k
Net Income -6.27M -6.2M 42.48M 36.66M
Change In Cash -2.58M -57.1k 42.08M 45.63M
Effect Of Exchange Rate
Total Cash From Operating Activities -4.08M -5.53M 28.17M 41.08M
Depreciation 50.77k 65.9k 138.63k 335.36k
Change To Account Receivables -13.42k -121.46k -12.96M -8.74M
Other Cashflows From Financing Activities -153.84k -592.76k -1.46M
Change To Netincome 1.37M 1.33M 2.37M 6.98M
Capital Expenditures -41.34k -113.25k -774.4k -669.46k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 1.36M 1.37M 3.19M 14.96M
Income Before Tax -6.27M -6.2M 42.57M 45.64M
Net Income -6.27M -6.2M 42.48M 36.66M
Selling General Administrative 4.74M 4.56M 12.94M 24.95M
Gross Profit 30.52k 102.54k 57.96M 86.31M
Ebit -6.12M -5.89M 41.69M 46.06M
Operating Income -6.12M -5.89M 41.69M 46.06M
Interest Expense -134.95k -106.44k
Income Tax Expense 90.54k 8.98M
Total Revenue 39.91k 214.97k 74.55M 97.89M
Cost Of Revenue 9.39k 112.43k 16.59M 11.57M
Total Other Income ExpenseNet -153.91k -301.82k 875.42k -429.16k
Net Income From Continuing Ops -6.27M -6.2M 42.48M 36.66M
Net Income Applicable To Common Shares -6.27M -6.2M 42.48M 36.66M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 2.61M 478.07k 4.54M 25.56M
Total Stockholder Equity -1.06M 1.74M 66.7M 134.48M
Other Current Liabilities 1.32k 495.04k 8.13M
Total Assets 1.55M 2.22M 71.24M 160.03M
Common Stock 12.92k 17.34k 28.56k 33.82k
Other Current Assets
Retained Earnings -18.69M -24.97M 17.51M 54.17M
Treasury Stock
Cash 950.24k 893.14k 42.98M 88.61M
Total Current Liabilities 2.35M 328.07k 4.06M 12.6M
Other Stockholder Equity
Property, Plant, and Equipment 156.14k 196.83k 949.64k 1.93M
Total Current Assets 1.05M 1.58M 67.81M 115.12M
Net Tangible Assets -1.06M 1.74M 66.7M 92.57M
Net Receivables 13.42k 131.38k 12.14M 20.91M
Accounts Payable 148.97k 5.96k 598.32k 607.51k


Insider Transactions

Here are the insider transactions of stock shares related to Co-Diagnostics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
SERBIN RICHARD SD2022-11-23Director11.67k
EGAN DWIGHT HD2022-11-23Chief Executive Officer79.17k
NELSON JAMES BD2022-11-23Director11.67k
MURPHY TEDD2022-11-23Director11.67k
DURENARD EUGENE AD2022-11-23Director11.67k
BROWN BRIAN LEED2022-11-23Chief Financial Officer59.17k
EGAN DWIGHT HStock Award(Grant) at price 0.00 per share.D2022-05-23Chief Executive Officer33.33k
EGAN DWIGHT HD2022-05-23Chief Executive Officer33.33k
BROWN BRIAN LEEStock Award(Grant) at price 0.00 per share.D2022-05-23Chief Financial Officer21.67k
BROWN BRIAN LEESale at price 4.99 per share.D2022-05-23Chief Financial Officer7.87k
BROWN BRIAN LEED2022-05-23Chief Financial Officer21.67k
SERBIN RICHARD SD2022-01-07Unknown12.5k
NELSON JAMES BD2022-01-07Unknown12.5k
MURPHY TEDStock Award(Grant) at price 0.00 per share.D2022-01-07Director12.5k
MURPHY TEDD2022-01-07Director12.5k
DURENARD EUGENE AStock Award(Grant) at price 0.00 per share.D2022-01-07Director12.5k
DURENARD EUGENE AConversion of Exercise of derivative security at price 9.28 per share.D2022-01-07Director25k
EGAN DWIGHT HStock Award(Grant) at price 0.00 per share.D2021-11-23Chief Executive Officer33.33k
EGAN DWIGHT HConversion of Exercise of derivative security at price 8.44 per share.D2021-11-23Chief Executive Officer187.5k
BROWN BRIAN LEEStock Award(Grant) at price 0.00 per share.D2021-11-23Chief Financial Officer21.67k
BROWN BRIAN LEEConversion of Exercise of derivative security at price 8.44 per share.D2021-11-23Chief Financial Officer125k
DURENARD EUGENE ASale at price 10.46 per share.D2021-09-08Director2k
BENSON REED LD2021-05-24General Counsel4.58k
EGAN DWIGHT HD2021-05-24Chief Executive Officer12.5k
BROWN BRIAN LEED2021-05-24Chief Financial Officer5k
BENSON REED LSale at price 8.52 - 8.54 per share.D2021-05-19General Counsel108.33k
BENSON REED LConversion of Exercise of derivative security at price 1.10 - 2.63 per share.D2021-05-19General Counsel108.33k
EGAN DWIGHT HSale at price 11.00 per share.D2021-01-15Chief Executive Officer38.05k
EGAN DWIGHT HConversion of Exercise of derivative security at price 2.63 per share.D2021-01-15Chief Executive Officer50k
SERBIN RICHARD SSale at price 10.29 per share.D2021-01-14Director10k
NELSON JAMES BSale at price 10.13 - 10.14 per share.D2021-01-13Director12.5k
DURENARD EUGENE ASale at price 10.09 per share.D2021-01-13Director10.5k
SERBIN RICHARD SSale at price 10.10 per share.D2020-12-14Director17k
DURENARD EUGENE ASale at price 10.15 per share.D2020-12-10Director10k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Co-Diagnostics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Co-Diagnostics Inc

Here is the result of two systematic investment strategies applied to Co-Diagnostics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Co-Diagnostics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Co-Diagnostics Inc:

Co-Diagnostics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 333.28% on the backtest period.

Performance at glance

Performance

333.28 %

Latent gain

5836.75 $

Invested capital

1751.31 $

Annualized return

81.29 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Co-Diagnostics Inc

This is the result of two momentum investment strategies applied to Co-Diagnostics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Co-Diagnostics Inc

The following chart shows all the entries opened by the momentum investment system on Co-Diagnostics Inc:

Co-Diagnostics Inc momentum entries
  • The first momentum investment strategy would give 287.48% of return on Co-Diagnostics Inc. That represents 12242.57$ of latent gain with 4258.58$ of employed capital.
  • The second momentum investment strategy would give 416.21% of return on Co-Diagnostics Inc. That represents 10391.48$ of latent gain with 2496.7$ of employed capital.
Performance at glance (1Q Momentum)

Performance

287.48 %

Latent gain

12242.57 $

Invested capital

4258.58 $

Annualized return

-16.17 %
Performance at glance (2Q Momentum)

Performance

416.21 %

Latent gain

10391.48 $

Invested capital

2496.7 $

Annualized return

114.98 %

Momentum equity curve on Co-Diagnostics Inc

The following chart shows the equity curve of the two momentum strategies applied to Co-Diagnostics Inc:

Co-Diagnostics Inc momentum equity

Note: the dividends potentially given by Co-Diagnostics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Co-Diagnostics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Co-Diagnostics Inc since the beginning:

Co-Diagnostics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Co-Diagnostics Inc

Buy the dip entry openings on Co-Diagnostics Inc

Co-Diagnostics Inc

The performance achieved by the robo-advisor on Co-Diagnostics Inc is -33.95%. That represents -84.6$ of latent gain with 249.2$ of employed capital. The following chart shows Co-Diagnostics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Co-Diagnostics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-33.95 %

Latent gain

-84.6 $

Invested capital

249.2 $

Annualized return

-16.17 %

Equity curve of the strategy applied to Co-Diagnostics Inc

The following chart shows the result of the investment strategy applied to Co-Diagnostics Inc:

Co-Diagnostics Inc

Note: the dividends potentially given by Co-Diagnostics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Co-Diagnostics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Co-Diagnostics Inc:

Co-Diagnostics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Co-Diagnostics Inc

In this section, I will compare the three previous investment strategies applied to Co-Diagnostics Inc.

Equity curve comparison on Co-Diagnostics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Co-Diagnostics Inc investment strategy comparison

Employed capital comparison on Co-Diagnostics Inc

Co-Diagnostics Inc investment comparison

Performance comparison on Co-Diagnostics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 333.28% 5836.75$ 1751.31$ 81.29%
Momentum 1 quarter 287.48% 12242.57$ 4258.58$ 74.48%
Momentum 2 quarters 416.21% 10391.48$ 2496.7$ 114.98%
Non-directional -33.95% -84.6$ 249.2$ -16.17%
Annualized return comparison

Automatic investment

81.29 %

Momentum 1Q

114.98 %

Momentum 2Q

114.98 %

Non-directional

-16.17 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Co-Diagnostics Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • MONGOLIA ENERGY
  • Dietswell S.A

  • Note: The algorithm computes the probability of correlation between Co-Diagnostics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Co-Diagnostics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Co-Diagnostics Inc
    Country United States
    City Salt Lake City
    Address 2401 South Foothill Drive
    Phone 801 438 1036
    Website www.codiagnostics.com
    FullTime employees 101
    Industry Medical Devices
    Sector Healthcare
    Exchange XNAS
    Ticker CODX
    Market www.nasdaq.com

    Co-Diagnostics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown